Cargando…

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model

Oncolytic ability to direct target and lyse tumor cells makes oncolytic virus therapy (OVT) a promising approach to treating cancer. Despite its therapeutic potential to stimulate anti-tumor immune responses, it also has immunosuppressive effects. The efficacy of OVTs as monotherapies can be enhance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jui-Ling, Jang, Sophia R.-J., Liu, Kwei-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914370/ https://www.ncbi.nlm.nih.gov/pubmed/36766849 http://dx.doi.org/10.3390/cells12030507

Ejemplares similares

Bilateral anterior uveitis after immunotherapy for malignant melanoma
por: Chang, Chia-Jui, et al.
Publicado: (2018)

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors
por: Li, Qingbo, et al.
Publicado: (2022)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Oncolytic viral immunotherapy in the time of COVID-19
por: Olagnier, David, et al.
Publicado: (2020)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
por: Zhang, Huan, et al.
Publicado: (2021)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy
por: Xu, Shengchao, et al.
Publicado: (2021)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Novel oncolytic viral therapies in patients with thoracic malignancies
por: Ahmad, Zeeshan, et al.
Publicado: (2016)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
por: Babiker, Hani M, et al.
Publicado: (2017)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
por: Sone, Kenbun, et al.
Publicado: (2022)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
por: Sampath, Padma, et al.
Publicado: (2015)

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
por: Innao, Vanessa, et al.
Publicado: (2020)

Oncolytic viruses in melanoma
por: Robinson, Camille, et al.
Publicado: (2022)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy
por: Zhou, De-Xi, et al.
Publicado: (2022)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)

Targeting Autophagy for Oncolytic Immunotherapy
por: Hu, Lulu, et al.
Publicado: (2017)

Oncolytic Alphaviruses in Cancer Immunotherapy
por: Lundstrom, Kenneth
Publicado: (2017)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy
por: Kim, Jihoon, et al.
Publicado: (2022)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Progress of immunotherapy in the treatment of malignant melanoma.
por: Ariyan, S.
Publicado: (1975)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d4br5vegrid1pct3qj8p7elsr0